GET DAILY SIGNALSProtara Therapeutics (TARA) Slides -24.7% as Dilution Risks and Extended Timelines Pressure Shares
Key Takeaways
- TARA shares declined roughly 24.7% over the last 30 days, from a closing price of $3.28 to about $2.47.
- The slide extends a broader multi-month downtrend, leaving the stock far below its 52-week high of $7.82 and below both its 50-day and 200-day moving averages.
- Investor pressure has been driven by dilution risk from a $100 million at-the-market facility, widening quarterly losses, and a clinical timeline that stretches toward a potential BLA submission in 2027.
- Second-quarter 2026 results showed a net loss of $21.7 million ($0.36 per share), missing consensus expectations, while research and development spending rose sharply.
- Short interest has climbed roughly 31% to about 10% of the float, reflecting elevated bearish positioning.
- Positive clinical updates across the ADVANCED-2, STARBORN-1, and THRIVE-3 programs have not yet offset financing and timeline concerns.
- For additional context on valuation, profitability, and projections, explore TARA's Price Targets, Earnings, and Forecast pages.
- Discover top-performing automated strategies across the market with Trending AI Robots.
Protara Therapeutics (TARA): Company Snapshot
Protara Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare diseases. Its lead candidate, TARA-002, is an investigational cell-based immunopotentiator derived from OK-432 (marketed as Picibanil in Japan) and is being evaluated for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). A second program, IV Choline Chloride, targets patients on long-term parenteral support who cannot meet their choline needs orally. The company is pre-revenue, has no approved products, and relies on its cash reserves to fund development. Investors follow TARA closely for clinical data readouts and regulatory milestones, given that value creation hinges on successful trial outcomes and eventual approvals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
TARA Stock Performance: Recent 30-Day and Quarterly Moves
Over the last 30 days, TARA shares fell approximately 24.7%, moving from a close of $3.28 to about $2.47. The decline was not linear: shares held near the $3.90 level into early September before a sharp, high-volume slide in late September and early October pushed the stock into the low-$2 range. The quarterly picture is similarly weak. The stock has been locked in a sustained downtrend, trading near $4.00 in mid-August before falling roughly 38% to current levels. Shares now sit well below their 50-day and 200-day moving averages, indicating persistent selling pressure across multiple timeframes rather than a single isolated event.
Factors Weighing on TARA Shares in the Past Month
Several factors weighed on TARA shares during the period. Financing and dilution concerns remained a central theme: the company has an at-the-market sales agreement allowing it to sell up to $100 million of common stock, and it raised $75 million in a December 2025 offering. For a pre-revenue company, the prospect of additional share issuance remains an overhang on sentiment. Fundamentals also contributed. Second-quarter results, reported in August, showed a net loss of $21.7 million, or $0.36 per share, missing consensus estimates, while R&D expenses climbed to $17.0 million from $10.8 million a year earlier. The combination of widening losses and rising spend highlighted the company's ongoing cash needs. Short interest rose about 31% to roughly 10% of the float, adding to downward pressure. Despite completing enrollment in the THRIVE-3 Phase 2b dose-confirmation phase in mid-October, the stock continued to drift lower, underscoring that near-term positive milestones have not outweighed financing and timeline concerns. From what I see, this combination continues to shape near-term sentiment.
Broader Quarterly Pressures on TARA Stock
The quarterly decline reflects a larger narrative around execution timelines and capital. After reaching a 52-week high of $7.82, the stock has steadily re-rated lower as investors weighed the path to potential commercialization. The planned Biologics License Application submission for TARA-002 in lymphatic malformations is targeted for the second half of 2027, meaning any meaningful product revenue remains years away. Meanwhile, repeated capital raises have diluted existing shareholders. Although the company has reported encouraging clinical data, including durable complete responses in NMIBC and strong efficacy in lymphatic malformations, the extended development horizon and ongoing financing requirements have kept sentiment subdued throughout the quarter. I’m watching this closely as the clinical updates unfold.
Key Catalysts Ahead for TARA Investors
Several near-term catalysts could influence TARA's trajectory. The company expects to complete enrollment of the BCG-unresponsive cohort of the ADVANCED-2 trial and to provide a STARBORN-1 update in the fourth quarter, alongside interim results from the THRIVE-3 Phase 2b cohort and the initiation of the redesigned ADVANCED-3 registrational trial. Upcoming quarterly earnings will also be closely watched for spending trends and cash runway commentary. Longer term, the BLA submission for TARA-002 in lymphatic malformations remains the pivotal regulatory milestone. Macroeconomic conditions, biotech-sector sentiment, and any additional capital-raising activity are key risks that could continue to shape the stock's direction. One thing that stands out is how these milestones line up against the financing backdrop.
Using AI Tools to Track Market Trends
In my own analysis, I frequently review Tickeron’s AI Trading Bots to monitor how automated strategies are performing across various market conditions and timeframes. These tools scan thousands of tickers and highlight consistently strong performers, which can offer useful perspective when evaluating names like TARA alongside broader sector moves. The selection refreshes based on live results, providing a practical way to cross-check manual research with data-driven signals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TARA's RSI Indicator recovers from oversold territory
The RSI Indicator for TARA moved out of oversold territory on October 26, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In 22 of the 24 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for TARA just turned positive on October 21, 2026. Looking at past instances where TARA's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Following a +10.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where TARA advanced for three days, in 174 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TARA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TARA as a result. In 79 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TARA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for TARA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.905) is normal, around the industry mean (3.037). P/E Ratio (-1.816) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. TARA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a clinical-stage company, which engages in developing treatments for rare and specialty diseases with significant unmet needs.
Industry Biotechnology
Advertisement